Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme

Background: Glioblastoma multiforme (GBM) is the most common and invasive primary central nervous system tumor. The prognosis after surgery, radiation and chemotherapy is very poor. Bromodomain (BRD) proteins have been identified in oncogenic rearrangements, and play a key role in the development of multiple cancers. However, the relationship between BET proteins and prognosis of GBM are still worth exploring, and the distinct functions of BET proteins and tumor immunology in GBM have not been fully elucidated. Therefore, it is particularly important to develop effective biomarkers to predict the prognosis of GBM patients. Methods: Metascape, David, Kaplan-Meier Plotter, Oncomine, GEPIA, TCGA, TIMER, and LinkedOmics databases were used to assess the expression and prognosis for BET proteins in GBM. ROC analysis of risk model was established to identify the correlation between BET genes and overall survival in GBM patients. TIMER and GEPIA databases were used to comprehensively investigate the correlation between BET genes and tumor immune infiltration cells. Moreover, the image of immunohistochemistry staining of BET proteins in normal tissue and tumor tissue were retrived from the HPA database. In addition, differential analysis and pathway enrichment analysis of BRD4 gene expression profile were also carried out. Finally, immune-fluorescence and Western blot were used to clarify the expression of BRD4 in GBM cells. Results: Bioinformatics analysis showed that the expression levels of BET genes in GBM may play an important role in oncogenesis. Specifically, bioinformatic and immunohistochemistry analysis showed that BRD4 protein was more highly expressed in tumor tissues than that in normal tissues. The high expression of BRD4 was associated with poor prognosis in GBM. The expression of BET genes were closely related to the immune checkpoint in GBM. The correlation effect of BRD4 was significantly higher than other BET genes, which represented negative correlation with immune checkpoint. The expression of BRD4 was positively associated with tumor purity, and negatively associated with immune infiltration abundance of macrophage, neutrophil and CD8+ T-cell, respectively. Cox analysis showed that the model had good survival prediction and prognosis discrimination ability. In addition, the expression levels of BRD4 protein was significantly higher in U-251 MG cells than that in normal cells, which was consistent with the results of bioinformatics data. Conclusion: This study implied that BRD4 could be hopeful prognostic biomarker in GBM. The increased expression of BRD4 may act as a molecular marker to identify GBM patients with high-risk subgroups. BRD4 may be a valuable prognostic biomarker, and a potential target of precision therapy against GBM.

[1]  XiaoWen Xu,et al.  An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16 , 2022, Cancer Chemotherapy and Pharmacology.

[2]  G. Kramer-Marek,et al.  Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations , 2022, OncoTargets and therapy.

[3]  Q. Qi,et al.  Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma , 2022, Journal of inflammation research.

[4]  Ju Huang,et al.  Bromodomain-containing protein 4 activates cardiotrophin-like cytokine factor 1, an unfavorable prognostic biomarker, and promotes glioblastoma in vitro , 2022, Annals of translational medicine.

[5]  Jinghua Ren,et al.  Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies. , 2022, Biomaterials science.

[6]  H. Daldrup-Link,et al.  Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. , 2021, Pharmacological research.

[7]  Hua You,et al.  BRD4: An emerging prospective therapeutic target in glioma , 2021, Molecular therapy oncolytics.

[8]  Q. Wei,et al.  Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database , 2021, Aging.

[9]  R. Mitra,et al.  Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma , 2017, Proceedings of the National Academy of Sciences.

[10]  M. Preusser,et al.  Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. , 2021, American journal of cancer research.

[11]  Huanming Yang,et al.  An atlas of the protein-coding genes in the human, pig, and mouse brain , 2020, Science.

[12]  Lu Xie,et al.  Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma , 2020, Cancer Cell International.

[13]  P. Schöffski,et al.  Make your best BET the emerging role of BET inhibitor treatment in malignant tumors. , 2020, Pharmacology & therapeutics.

[14]  Shou-ping Gong,et al.  BRD4 promotes glioma cell stemness via enhancing miR‐142‐5p‐mediated activation of Wnt/β‐catenin signaling , 2019, Environmental toxicology.

[15]  L. Derré,et al.  The multifaceted immune regulation of bladder cancer , 2019, Nature Reviews Urology.

[16]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[17]  Xu Zhou,et al.  Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy , 2019, Nature Medicine.

[18]  Z. Ballas.  The 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology. , 2018, The Journal of allergy and clinical immunology.

[19]  A. Ciarrocchi,et al.  BRD4 and Cancer: going beyond transcriptional regulation , 2018, Molecular Cancer.

[20]  S. Günther,et al.  Bromodomain Drug Discovery - the Past, the Present, and the Future. , 2018, Chemical record.

[21]  J. Barnholtz-Sloan,et al.  Epidemiology of Brain Tumors. , 2018, Neurologic clinics.

[22]  N. Butowski,et al.  Primary brain tumours in adults , 2018, The Lancet.

[23]  A. Zhavoronkov,et al.  Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.

[24]  T. Yuan,et al.  Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression , 2018, Cancer biology & therapy.

[25]  P. Wesseling,et al.  WHO 2016 Classification of gliomas , 2018, Neuropathology and applied neurobiology.

[26]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[27]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[28]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[29]  Ludmila V. Danilova,et al.  Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[30]  P. Tak,et al.  The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts , 2014, Annals of the rheumatic diseases.

[31]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[32]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[33]  Paul Shinn,et al.  Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.

[34]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[35]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[36]  Claes Wahlestedt,et al.  BET bromodomain proteins are required for glioblastoma cell proliferation , 2014, Epigenetics.

[37]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[38]  M. Dawson,et al.  Bromodomains as therapeutic targets in cancer. , 2013, Briefings in functional genomics.

[39]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[40]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[41]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[42]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[43]  Tahsin Kurc,et al.  The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. , 2012, The American journal of pathology.

[44]  H. Kettenmann,et al.  The brain tumor microenvironment , 2011, Glia.

[45]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[46]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[47]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[48]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[49]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.